Lipase News and Research

RSS

Women with defects in lipoprotein metabolism may actually be able to bear children without complications

A group of Belgian researchers has determined that a pregnant woman's ability to metabolize fats is determined not only by her genes but by her baby's genes as well.

30 Oct 2005

Naturally produced 'cannabis' in the brain helps with pain relief

Researchers in the United States have found that a cannabis like chemical produced naturally in the brain helps with pain relief.

23 Jun 2005

Orlistat, a drug that decreases fat absorption, appears helpful for improving weight management in obese adolescents

When combined with diet, exercise and behavioral therapy, orlistat, a drug that decreases fat absorption, appears helpful for improving weight management in obese adolescents, compared with placebo, according to an article in the June 15 issue of JAMA: The Journal of the American Medical Association.

14 Jun 2005

Clinical trial of lipase inhibitor for the treatment of obesity

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.

9 Aug 2004

FDA requires pancreatic extract manufacturers to get approval to remain on the market

The Food and Drug Administration (FDA) today formally notified manufacturers of pancreatic insufficiency products that these drugs must get approval by FDA within the next four years in order to remain on the market.

28 Apr 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004

Research suggests the orlistat drug could be used to fight cancer and obesity

The Burnham Institute’s Jeffrey Smith, Ph.D., has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004

Obesity Drug Inhibits Prostate Tumor Growth

The Burnham Institute's Jeffrey Smith, Ph.D. has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004